Rosen Law Firm has filed a class action lawsuit against Lincoln Educational Services Corporation for allegedly making false and misleading statements about its student admissions process between May 11 and August 9, 2026. The lawsuit claims Lincoln misrepresented its ability to convert student enrollments into actual starts, causing investors to suffer losses when the truth emerged. Investors who bought Lincoln securities during this period may join the lawsuit and seek compensation without upfront fees. Interested parties must act by November 10, 2026, to become lead plaintiff in the case.
Lincoln Educational Services Corporation securities fraud lawsuit is the subject, with Pluang's Consumer Cyclical sector data providing market context. For readers following this sector, as of Sep 16, 2026 02:31 WIB, 10 of 105 priced US stocks rose while 95 fell. Notable movers include Allbirds Inc (BIRD) at USD 2.37 down 5.58%, Stitch Fix Inc (SFIX) at USD 2.93 down 5.18%, and Kohl's Corporation (KSS) at USD 16.32 down 4.90%.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
